226 related articles for article (PubMed ID: 19479667)
21. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
22. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
[TBL] [Abstract][Full Text] [Related]
23. Emulsion-based adjuvants for influenza vaccines.
Vogel FR; Caillet C; Kusters IC; Haensler J
Expert Rev Vaccines; 2009 Apr; 8(4):483-92. PubMed ID: 19348563
[TBL] [Abstract][Full Text] [Related]
24. Vaccines in development against avian influenza.
Cox MM
Minerva Med; 2007 Apr; 98(2):145-53. PubMed ID: 17519856
[TBL] [Abstract][Full Text] [Related]
25. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
[TBL] [Abstract][Full Text] [Related]
26. Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine.
Philippa J; Baas C; Beyer W; Bestebroer T; Fouchier R; Smith D; Schaftenaar W; Osterhaus A
Vaccine; 2007 May; 25(19):3800-8. PubMed ID: 17403559
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
28. Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
Baras B; Stittelaar KJ; Kuiken T; Jacob V; Bernhard R; Giannini S; de Waal L; van Amerongen G; Simon JH; Osterhaus AD; Hanon E; Mossman SP
Vaccine; 2011 Mar; 29(11):2092-9. PubMed ID: 21237275
[TBL] [Abstract][Full Text] [Related]
29. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of inactivated vaccines against H5N1 avian influenza infection in ducks.
Middleton D; Bingham J; Selleck P; Lowther S; Gleeson L; Lehrbach P; Robinson S; Rodenberg J; Kumar M; Andrew M
Virology; 2007 Mar; 359(1):66-71. PubMed ID: 17028058
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
[TBL] [Abstract][Full Text] [Related]
32. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry.
Worrall EE; Sudarisman ; Priadi A
Vaccine; 2009 Jun; 27(31):4161-8. PubMed ID: 19406183
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
34. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
[TBL] [Abstract][Full Text] [Related]
35. Development of vaccines against influenza A virus (H5N1).
Li WC; Huang YC
Chang Gung Med J; 2007; 30(4):294-304. PubMed ID: 17939259
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
Jadhao SJ; Lee CW; Sylte M; Suarez DL
Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
[TBL] [Abstract][Full Text] [Related]
37. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
38. The immunogenicity and efficacy against H5N1 challenge of reverse genetics-derived H5N3 influenza vaccine in ducks and chickens.
Webster RG; Webby RJ; Hoffmann E; Rodenberg J; Kumar M; Chu HJ; Seiler P; Krauss S; Songserm T
Virology; 2006 Aug; 351(2):303-11. PubMed ID: 16690097
[TBL] [Abstract][Full Text] [Related]
39. Strategies for developing vaccines against H5N1 influenza A viruses.
Horimoto T; Kawaoka Y
Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
[TBL] [Abstract][Full Text] [Related]
40. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
